Effects of hormone therapy on brain structure

Objective: To investigate the effects of hormone therapy on brain structure in a randomized, double-blinded, placebo-controlled trial in recently postmenopausal women. Methods: Participants (aged 42–56 years, within 5–36 months past menopause) in the Kronos Early Estrogen Prevention Study were randomized to (1) 0.45 mg/d oral conjugated equine estrogens (CEE), (2) 50 μg/d transdermal 17β-estradiol, or (3) placebo pills and patch for 48 months. Oral progesterone (200 mg/d) was given to active treatment groups for 12 days each month. MRI and cognitive testing were performed in a subset of participants at baseline, and at 18, 36, and 48 months of randomization (n = 95). Changes in whole brain, ventricular, and white matter hyperintensity volumes, and in global cognitive function, were measured. Results: Higher rates of ventricular expansion were observed in both the CEE and the 17β-estradiol groups compared to placebo; however, the difference was significant only in the CEE group (p = 0.01). Rates of ventricular expansion correlated with rates of decrease in brain volume (r = −0.58; p ≤ 0.001) and with rates of increase in white matter hyperintensity volume (r = 0.27; p = 0.01) after adjusting for age. The changes were not different between the CEE and 17β-estradiol groups for any of the MRI measures. The change in global cognitive function was not different across the groups. Conclusions: Ventricular volumes increased to a greater extent in recently menopausal women who received CEE compared to placebo but without changes in cognitive performance. Because the sample size was small and the follow-up limited to 4 years, the findings should be interpreted with caution and need confirmation. Classification of evidence: This study provides Class I evidence that brain ventricular volume increased to a greater extent in recently menopausal women who received oral CEE compared to placebo.

[1]  Armando Manduca,et al.  Methodological considerations for measuring rates of brain atrophy , 2003, Journal of magnetic resonance imaging : JMRI.

[2]  C. Jack,et al.  Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women , 2013, Neurology.

[3]  Jennifer G. Robinson,et al.  Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. , 2013, JAMA internal medicine.

[4]  Belinda Pletzer,et al.  Menstrual cycle and hormonal contraceptive use modulate human brain structure , 2010, Brain Research.

[5]  Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy: A Randomized Controlled Trial , 2011 .

[6]  J. Kaye,et al.  Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia , 1997, Neurology.

[7]  J. Janowsky,et al.  Hormone replacement therapy and cognition: systematic review and meta-analysis. , 2001, JAMA.

[8]  Frederick Naftolin,et al.  Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study , 2015, PLoS medicine.

[9]  W. Rocca,et al.  Oophorectomy, estrogen, and dementia: A 2014 update , 2014, Molecular and Cellular Endocrinology.

[10]  J. Manson,et al.  Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. , 2014, Annals of internal medicine.

[11]  E G Tangalos,et al.  Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.

[12]  B. Sherwin Estrogen and memory in women: how can we reconcile the findings? , 2005, Hormones and Behavior.

[13]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[14]  Brenda L Plassman,et al.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.

[15]  J. Manson,et al.  Characterization of Vascular Disease Risk in Postmenopausal Women and Its Association with Cognitive Performance , 2013, PloS one.

[16]  J. Kril,et al.  Neuropathologic correlates of white matter hyperintensities , 2008, Neurology.

[17]  M A Espeland,et al.  The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. , 1998, Controlled clinical trials.

[18]  K. Yaffe,et al.  Timing of hormone therapy and dementia: The critical window theory revisited , 2011, Annals of neurology.

[19]  C Davatzikos,et al.  Postmenopausal hormone therapy and regional brain volumes , 2009, Neurology.

[20]  Lewis H Kuller,et al.  Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. , 2009, American journal of epidemiology.

[21]  W. Jagust,et al.  Preliminary evidence that estrogen protects against age-related hippocampal atrophy , 2003, Neurobiology of Aging.

[22]  Wiro J Niessen,et al.  POSTMENOPAUSAL HORMONE THERAPY AND REGIONAL BRAIN VOLUMES: THE WHIMS-MRI STUDY , 2009, Neurology.

[23]  M. Kraut,et al.  Estrogen Replacement Therapy and MRI‐Demonstrated Cerebral Infarcts, White Matter Changes, and Brain Atrophy in Older Women: The Cardiovascular Health Study , 2000, Journal of the American Geriatrics Society.

[24]  B. Condon,et al.  Is Cranial CSF Volume Under Hormonal Influence? An MR Study , 1988, Journal of computer assisted tomography.

[25]  Nick C Fox,et al.  Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.

[26]  K. Yaffe,et al.  Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.

[27]  Christos Davatzikos,et al.  Change in brain and lesion volumes after CEE therapies , 2014, Neurology.

[28]  Suzanne E. Welcome,et al.  Mapping cortical change across the human life span , 2003, Nature Neuroscience.

[29]  Marina Boccardi,et al.  Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study , 2006, Menopause.

[30]  S. Asthana,et al.  Effects of hormone therapy on cognition and mood. , 2014, Fertility and sterility.

[31]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[32]  D. Steffens,et al.  Differences in brain volumes among males and female hormone-therapy users and nonusers , 2006, Psychiatry Research: Neuroimaging.

[33]  Jingang Xu,et al.  Preliminary evidence that long-term estrogen use reduces white matter loss in aging , 2007, Neurobiology of Aging.

[34]  C. Lord,et al.  Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: A possible window of opportunity effect , 2008, Neurobiology of Aging.

[35]  David Silbersweig,et al.  Hippocampal structural changes across the menstrual cycle , 2008, Hippocampus.

[36]  P. Nederkoorn,et al.  Cerebral small-vessel disease and progression of brain atrophy , 2012, Neurology.

[37]  Dong-Sun Han,et al.  C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-α and the critical period hypothesis of estrogen neuroprotection , 2011, Proceedings of the National Academy of Sciences.

[38]  J. Manson,et al.  Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. , 2011, JAMA.

[39]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[40]  S. Resnick,et al.  Brain volumes, cognitive impairment, and conjugated equine estrogens. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[41]  J. Manson,et al.  KEEPS: The Kronos Early Estrogen Prevention Study , 2005, Climacteric : the journal of the International Menopause Society.

[42]  Thomas Behrenbeck,et al.  Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. , 2008, American journal of physiology. Heart and circulatory physiology.

[43]  H Kuhl,et al.  Pharmacology of estrogens and progestogens: influence of different routes of administration , 2005, Climacteric : the journal of the International Menopause Society.

[44]  S. Davis,et al.  Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years , 2015, Menopause.